These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10503157)

  • 1. Apples, oranges, forests, and trees.
    Cushman R
    J Health Polit Policy Law; 1999 Aug; 24(4):763-8. PubMed ID: 10503157
    [No Abstract]   [Full Text] [Related]  

  • 2. The which-hunt: assembling health technologies for assessment and rationing.
    Giacomini MK
    J Health Polit Policy Law; 1999 Aug; 24(4):715-58. PubMed ID: 10503155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
    Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
    Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From principle to public policy: using cost-effectiveness analysis.
    Neumann PJ; Johannesson M
    Health Aff (Millwood); 1994; 13(3):206-14. PubMed ID: 7927151
    [No Abstract]   [Full Text] [Related]  

  • 6. How can Medicare keep pace with cutting-edge technology?
    Buto KA
    Health Aff (Millwood); 1994; 13(3):137-40. PubMed ID: 7927144
    [No Abstract]   [Full Text] [Related]  

  • 7. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reimbursing new technologies: why are the courts judging experimental medicine?
    Saver RS
    Stanford Law Rev; 1992 May; 44(5):1095-131. PubMed ID: 10119850
    [No Abstract]   [Full Text] [Related]  

  • 9. Hospital policy: proposing and disposing.
    Curtin LL
    Nurs Manage; 1992 Sep; 23(9):21-4, 26. PubMed ID: 1518612
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient Preferences in the Medical Product Lifecycle.
    Whitty JA; de Bekker-Grob EW; Cook NS; Terris-Prestholt F; Drummond M; Falchetto R; Hillege HL
    Patient; 2020 Feb; 13(1):7-10. PubMed ID: 31782120
    [No Abstract]   [Full Text] [Related]  

  • 11. The limited regulatory potential of medical technology assessment.
    Elhauge E
    Va Law Rev; 1996 Nov; 82(8):1525-1622. PubMed ID: 16715565
    [No Abstract]   [Full Text] [Related]  

  • 12. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
    Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review.
    Löblová O; Trayanov T; Csanádi M; Ozierański P
    Value Health; 2020 Jan; 23(1):3-9. PubMed ID: 31952670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical necessity: trying to reach consensus.
    Phillips L
    Hosp Technol Ser; 1996 May; 15(6):5, 10. PubMed ID: 10158519
    [No Abstract]   [Full Text] [Related]  

  • 15. Does assessment of medical practices have a future?
    Capron AM
    Va Law Rev; 1996 Nov; 82(8):1623-40. PubMed ID: 16715566
    [No Abstract]   [Full Text] [Related]  

  • 16. When an insurer calls your treatment experimental.
    Holoweiko M
    Med Econ; 1995 Sep; 72(17):171-2, 175-6, 178-82. PubMed ID: 10151340
    [No Abstract]   [Full Text] [Related]  

  • 17. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
    Fisfis BA
    Spec Law Dig Health Care Law; 1994 Mar; (181):9-32. PubMed ID: 10133063
    [No Abstract]   [Full Text] [Related]  

  • 18. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria should be set by congress, payers, not ESRD community.
    Burrows-Hudson S
    Nephrol News Issues; 1992 Feb; 6(2):31. PubMed ID: 1557149
    [No Abstract]   [Full Text] [Related]  

  • 20. Experimental therapy--who shall pay?
    N Engl J Med; 1991 May; 324(18):1291-2. PubMed ID: 2014045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.